Targeting PTBP1 blocks glutamine metabolism to improve the cisplatin sensitivity of hepatocarcinoma cells through modulating the mRNA stability of glutaminase

Hepatocellular carcinoma (HCC) is a frequently diagnosed malignancy with a high mortality rate. Cisplatin (CDDP) is a widely applied anti-cancer drug. However, a large population of liver cancer patients developed CDDP resistance. The polypyrimidine tract binding protein (PTBP1) is an RNA-binding pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Ruimin, Li, Yanfei, Shen, Xiaojie, Li, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505300/
https://www.ncbi.nlm.nih.gov/pubmed/37724122
http://dx.doi.org/10.1515/med-2023-0756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505300/
https://www.ncbi.nlm.nih.gov/pubmed/37724122
http://dx.doi.org/10.1515/med-2023-0756

Ejemplares similares